LMCD1 (LIM and cysteine rich domains 1) is a transcriptional cofactor that plays crucial roles in muscle function and disease pathogenesis. The protein contains a novel cysteine-rich domain in the amino-terminal region and two LIM domains in the carboxy-terminal region, with highest expression in skeletal muscle 1. In skeletal muscle, LMCD1 acts as a positive regulator of muscle mass, increasing protein synthesis, fiber size, and specific force while reducing muscle fatigue through calcineurin-dependent mechanisms 2. LMCD1 represses myoregulin expression, a negative regulator of muscle performance, and its reduced expression is associated with skeletal muscle diseases 2. In cardiac contexts, LMCD1 has been identified as a potential drug target for chr3 obstructive pulmonary disease through Mendelian randomization analysis 3. Additionally, LMCD1 is implicated in mitral valve prolapse through genome-wide association studies 4 and lung function regulation across multiple tissues 5. Recent research has also identified LMCD1's role in sepsis-associated acute kidney injury, where GATA1 transcriptionally upregulates LMCD1, promoting ferroptosis through the Hippo/YAP pathway 6. These findings establish LMCD1 as a multifunctional transcriptional regulator with significant therapeutic potential across various tissue systems.